Header Logo

David D.Hurd MD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine, Hematology & Oncology
Address
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U10CA003927     (HURD, DAVID D)Apr 1, 1979 - Mar 31, 2009
    NIH
    Cancer and Leukemia Group B
    Role: Principal Investigator
    R21CA085416     (HURD, DAVID D)Mar 1, 2001 - Feb 29, 2004
    NIH
    DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vij R, Le-Rademacher J, Laumann K, Hars V, Owzar K, Shore T, Vasu S, Cashen A, Isola L, Shea T, DeMagalhaes-Silverman M, Hurd D, Meehan K, Beardell F, Devine S. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biol Blood Marrow Transplant. 2019 10; 25(10):1984-1992. PMID: 31212080.
      Citations:    
    2. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073. PMID: 29437791.
      Citations:    
    3. Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma. 2018 08; 59(8):1871-1877. PMID: 29252084.
      Citations:    
    4. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442. PMID: 28826616.
      Citations:    
    5. Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):424-432. PMID: 28655599.
      Citations:    
    6. Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):76-81. PMID: 26725264.
      Citations:    
    7. Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, McIver Z. Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Clin Case Rep. 2015 Jul; 3(7):615-7. PMID: 26273453.
      Citations:    
    8. Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ. Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol. 2015 Mar; 13(3):87-94. PMID: 26287032.
      Citations:    
    9. Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13. PMID: 24838014.
      Citations:    
    10. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64. PMID: 25165100.
      Citations:    
    11. Duckworth KE, Forti AM, Russell GB, Naik S, Hurd DD, McQuellon RP. Hematopoietic stem cell transplant candidate and designated proxy distress levels prior to hematopoietic stem cell transplantation. Am J Hosp Palliat Care. 2014 Dec; 31(8):853-6. PMID: 24142596.
      Citations:    
    12. Duckworth KE, Forti AM, Russell GB, Naik S, Hurd D, McQuellon RP. The process of advance care planning in HCT candidates and proxies: self-efficacy, locus of control, and anxiety levels. Am J Hosp Palliat Care. 2014 Nov; 31(7):710-6. PMID: 23946253.
      Citations:    
    13. Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20. PMID: 23700288.
      Citations:    
    14. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. PMID: 22571201.
      Citations:    
    15. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012 Sep-Oct; 10(5):195-201. PMID: 22266154.
      Citations:    
    16. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65. PMID: 22133772.
      Citations:    
    17. Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar; 53(3):417-23. PMID: 21879809.
      Citations:    
    18. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10; 118(19):5119-25. PMID: 21937701.
      Citations:    
    19. Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr; 52(4):587-96. PMID: 21275630.
      Citations:    
    20. Pomper GJ, Wilson E, Isom S, Hurd DD. A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory. Transfusion. 2011 Jun; 51(6):1291-5. PMID: 21658038.
      Citations:    
    21. Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011 Apr; 22(4):939-946. PMID: 20935058.
      Citations:    
    22. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33. PMID: 20688393.
      Citations:    
    23. Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant. 2011 Apr; 17(4):558-65. PMID: 20674758.
      Citations:    
    24. Keung YK, Beaty MW, Pettenati M, Levitan D, Hurd DD. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Clin Lymphoma Myeloma Leuk. 2010 Apr; 10(2):129-33. PMID: 20371446.
      Citations:    
    25. Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J. Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction. J Soc Integr Oncol. 2010; 8(4):140-147. PMID: 24619452.
      Citations:    
    26. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8. PMID: 19917845.
      Citations:    
    27. Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Grover M, Lovato J, Torti SV, Torti FM, Molnár I. The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol. 2009 Oct 24; 2:44. PMID: 19852846.
      Citations:    
    28. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96. PMID: 19863336.
      Citations:    
    29. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13. PMID: 19747781.
      Citations:    
    30. Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008 Nov; 48(11):2285-91. PMID: 18673350.
      Citations:    
    31. Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8. PMID: 18452072.
      Citations:    
    32. Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol. 2008 May 10; 26(14):2240-3. PMID: 18467711.
      Citations:    
    33. Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007 Dec; 13(12):1469-76. PMID: 18022577.
      Citations:    
    34. Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy. 2007 Oct; 27(10):1353-60. PMID: 17896890.
      Citations:    
    35. Huff JD, Keung YK, Thakuri M, Beaty MW, Hurd DD, Owen J, Molnár I. Copper deficiency causes reversible myelodysplasia. Am J Hematol. 2007 Jul; 82(7):625-30. PMID: 17236184.
      Citations:    
    36. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May; 2(5):445-9. PMID: 17473661.
      Citations:    
    37. Linker C, Hurd D. The cancer and leukemia group B transplant committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3635s-7s. PMID: 16740798.
      Citations:    
    38. Connor RF, Hurd D, Pettenati MJ, Koty P, Molnár I. Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia. Leuk Res. 2006 Oct; 30(10):1249-52. PMID: 16580068.
      Citations:    
    39. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20; 24(6):929-36. PMID: 16432076.
      Citations:    
    40. Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9. PMID: 16118805.
      Citations:    
    41. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200. PMID: 15767638.
      Citations:    
    42. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301. PMID: 15514371.
      Citations:    
    43. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, Shea TC, Brunvand MM, Vaughan W, Petersen F, Schubert M, Lazarus HM, Maziarz RT, Silverman M, Beveridge RA, Redman R, Pulliam JG, Devitt-Risse P, Fuchs HJ, Hurd DD. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res. 2004 Jun; 28(6):559-65. PMID: 15120931.
      Citations:    
    44. Dodge W, Cruz J, Zamkoff K, Hurd D, Pettenati MJ. Use of fluorescence in situ hybridization to detect minimal residual disease in hematopoietic stem cell assays from peripheral blood stem cells of 2 patients with trisomy 8 acute myeloid leukemia. Stem Cells Dev. 2004 Feb; 13(1):23-6. PMID: 15068690.
      Citations:    
    45. Keung YK, Knovich MA, Hurd DD, Pettenati M. Constitutional pericentric inversion of chromosome 9 and bone marrow transplantation. Br J Haematol. 2003 Nov; 123(4):748-9. PMID: 14616986.
      Citations:    
    46. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan NA. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003 Aug; 9(8):512-8. PMID: 12931120.
      Citations:    
    47. Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR, Sonis ST, Martin PJ, Giles F. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer. 2003 Jul 15; 98(2):406-12. PMID: 12872363.
      Citations:    
    48. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma. 2003 Jul; 44(7):1165-72. PMID: 12916869.
      Citations:    
    49. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80. PMID: 12627512.
      Citations:    
    50. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. PMID: 12668651.
      Citations:    
    51. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003 Jan 01; 21(1):5-15. PMID: 12506163.
      Citations:    
    52. High KP, Legault C, Sinclair JA, Cruz J, Hill K, Hurd DD. Low plasma concentrations of retinol and alpha-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. Am J Clin Nutr. 2002 Dec; 76(6):1358-66. PMID: 12450904.
      Citations:    
    53. Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 2002 Jul 16; 137(2):77-87. PMID: 12118962.
      Citations:    
    54. Kaya H, Keung YK, Case D, Cruz JM, Perry JJ, Radford JE, Hurd DD. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2002; 8(10):544-9. PMID: 12434949.
      Citations:    
    55. Keung YK, Pettenati M, Hurd DD, Powell BL, Buss DH. Allogenic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9. Br J Haematol. 2002 Jan; 116(1):237-8. PMID: 11848092.
      Citations:    
    Hurd's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (275)
    Explore
    _
    Co-Authors (21)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _